Biopharmaceutical company InflaRx, which specializes in pioneering anti-inflammatory therapeutics, has secured $150.0M in new capital. The funding comes as the company continues to advance its proprietary anti-C5a and anti-C5aR technologies, aiming to develop highly potent inhibitors for various inflammatory diseases.
Founded in 2007, InflaRx is known for its lead product candidate, vilobelimab, a novel anti-C5a monoclonal antibody. It is also developing INF904, an orally administered C5a receptor inhibitor, with operations spanning Germany and the U.S.















